Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 8.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 966,129 shares of the company’s stock after purchasing an additional 75,081 shares during the period. Geode Capital Management LLC’s holdings in Spyre Therapeutics were worth $22,498,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Barclays PLC grew its stake in Spyre Therapeutics by 64.7% during the 3rd quarter. Barclays PLC now owns 105,467 shares of the company’s stock worth $3,101,000 after buying an additional 41,424 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Spyre Therapeutics during the 4th quarter worth approximately $290,000. Victory Capital Management Inc. purchased a new position in Spyre Therapeutics in the fourth quarter worth $6,241,000. Jane Street Group LLC lifted its stake in shares of Spyre Therapeutics by 78.7% in the third quarter. Jane Street Group LLC now owns 20,641 shares of the company’s stock valued at $607,000 after purchasing an additional 9,090 shares during the period. Finally, State Street Corp lifted its position in shares of Spyre Therapeutics by 9.4% during the 3rd quarter. State Street Corp now owns 1,541,555 shares of the company’s stock valued at $45,337,000 after acquiring an additional 131,896 shares during the period. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Trading Up 2.0 %

Shares of NASDAQ:SYRE opened at $12.67 on Friday. Spyre Therapeutics, Inc. has a 12-month low of $10.91 and a 12-month high of $40.49. The stock’s 50-day moving average price is $17.44 and its two-hundred day moving average price is $23.78. The firm has a market cap of $763.70 million, a price-to-earnings ratio of -1.70 and a beta of 3.05.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.08. As a group, research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SYRE. Wedbush reaffirmed an “outperform” rating and set a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, January 13th. Leerink Partners began coverage on Spyre Therapeutics in a report on Tuesday, April 8th. They issued an “outperform” rating and a $45.00 price target for the company. Leerink Partnrs raised Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, April 8th. Wolfe Research began coverage on shares of Spyre Therapeutics in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $27.00 target price for the company. Finally, The Goldman Sachs Group raised shares of Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 18th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $49.57.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).